Newsroom
25/08/2010
Company Statement - Shelf Life Reduction of Panvax® Junior
Ongoing monitoring by both CSL and the TGA of CSL’s Panvax
® Junior vaccine has shown a decline in its potency and as a result a 12 month shelf life can no longer be supported. Panvax
® Junior is the paediatric presentation of CSL’s 2009 H1N1 (pandemic) influenza vaccine, which is supplied in a single 0.25ml pre-filled syringe.
More.
15/07/2010
CSL Announces New Biotech Facility
CSL Limited today announced a major biotechnology project at CSL’s manufacturing site in Broadmeadows, Australia. The centrepiece of the project will be the creation of Victoria’s first large scale biotechnology facility for the late stage development of new therapies for cancer, bleeding disorders, inflammation and infection.
More.
29/06/2010
Media Statement - CSL receive "Untitled Letter" from FDA
On 24 June 2010, CSL received an “Untitled Letter” from the United States Food and Drug Administration (FDA) relating to a routine inspection it conducted at our Parkville manufacturing facility in April 2010. The inspection related to CSL’s seasonal and pandemic influenza vaccines licensed for use in the United States.
More.
21/12/2009
Findings of Australian trial of CSL’s Pandemic (H1N1) 2009
CSL Limited, Australia’s leading biopharmaceutical company, announced the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study CSL’s pandemic H1N1 2009 ‘swine' flu vaccine.
More.
10/12/2009
Vaccine to treat gum disease on the way
CSL Limited, Australia’s leading biopharmaceutical company, has today announced that a vaccine to treat severe gum disease is being developed in a new collaboration with Sanofi Pasteur, the world’s leading global manufacturer of vaccines.
More.
08/12/2009
CHANGES TO CSL SENIOR EXECUTIVE GROUP
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years.
More.
>>
Prior Archived Newsroom
Media Enquiries - CSL Limited Sharon McHale Senior Director Public Affairs Phone: +613 9389 1506 Mobile: +61 409 978 314 Email:
sharon.mchale@csl.com.au 45 Poplar Rd, Parkville Victoria 3052 Australia | Media Enquiries - CSL Behring Kelly Fox Phone: +1 610 878 4369 Fax: +1 610 878 4584 Email: kelly.fox@cslbehring.com 1020 First Avenue PO Box 61501 King of Prussia, PA 19406-0901 USA |